NR and Inflammation. 

The decline in NAD+ in the brain that comes with aging contributes to cellular and metabolic dysfunction and can be implicated in age-associated neurological disorders. This clinical study demonstrates that orally administered NR can augment neuronal NAD+ levels and affect biomarkers related to neurodegeneration in humans.

An ever-growing body of clinical evidence demonstrates that NR may reduce inflammation and has the potential for more robust effects among the elderly or diseased populations who tend to have compromised NAD+ and have a higher inflammatory status. However, more research is needed to clarify which inflammatory markers are targeted by nicotinamide riboside (NR), and the extent to which they are modified by dose and demographics. 

There are now eight clinical studies that demonstrate NR’s anti-inflammatory effect either alone or in combination with other ingredients (Elhassan et al., 2019Remie et al., 2020Zhou et al., 2020Altay et al., 2021Zeybel et al., 2021Brakedal et al., 2022Wang et al., 2022Wu et al., 2022). Managing inflammation is fundamental to optimizing health, supporting immune function, and recovering from physical activity (Buonocore et al., 2015 ). Underlying chronic inflammation appears to be a consistent factor in age-associated functional decline, even in relatively healthy individuals (Singh and Newman, 2011).The learnings from the following eight studies demonstrate how NAD+ precursors may play a role in managing inflammation. For those who are interested in reviewing the study details regarding dosage, population, and primary outcomes regarding the role of NR in reducing inflammatory markers, we have created an easy-to-digest table below summarizing the facts. You may need to click on “Download external images” located below the email subject line to view this table. Please let us know if you have any questions.
(Source: Chromadex)

Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE

Visit HPA-China’s Information Hub, HERE

*Nutritional cocktail termed “Combined Metabolic Activators,” comprised of 1000mg NR, 12.35g L-serine, 3.73g L-carnitine tartrate, 2.55g N-acetylcysteine (NAC).

References:Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., et al. (2021). “Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19.” Adv Sci 8, 2101222. doi: 10.1002/advs.202101222.Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., et al. (2022). “The NADPARK study: A Randomized Phase I Trial of Nicotinamide Riboside Supplementation in Parkinson’s Disease.” Cell Metab 34, 396-407.e6. doi: 10.1016/j.cmet.2022.02.001.Buonocore, D., Negro, M., Arcelli, E., and Marzatico, F. (2015). “Anti-Inflammatory Dietary Interventions and Supplements to Improve Performance During Athletic Training.” J Am Coll Nutr 34, 62–67. doi: 10.1080/07315724.2015.1080548.Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., et al. (2019). “Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.” Cell Reports 28, 1717-1728.e6. doi: 10.1016/j.celrep.2019.07.043.Remie, C. M. E., Roumans, K. H. M., Moonen, M. P. B., Connell, N. J., Havekes, B., Mevenkamp, J., et al. (2020). “Nicotinamide Riboside Supplementation Alters Body Composition and Skeletal Muscle Acetylcarnitine Concentrations in Healthy Obese Humans.” Am J Clin Nutrition 112, 413–426. doi: 10.1093/ajcn/nqaa072.Singh, T., and Newman, A. B. (2011). “Inflammatory Markers in Population Studies of Aging.” Ageing Res Rev 10, 319–329. doi: 10.1016/j.arr.2010.11.002.Wang, D. D., Airhart, S. E., Zhou, B., Shireman, L. M., Jiang, S., Rodriguez, C. M., et al. (2022). “Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction.” Jacc Basic Transl Sci. doi: 10.1016/j.jacbts.2022.06.012.Wu, J., Singh, K., Lin, A., Meadows, A. M., Wu, K., Shing, V., et al. (2022). “Boosting NAD+ Blunts Toll-Like Receptor-4 Induced Type-I Interferon in Control and Systemic Lupus Erythematosus Monocytes.” J Clin Invest 132, e139828. doi: 10.1172/jci139828.Zeybel, M., Altay, O., Arif, M., Li, X., Yang, H., Fredolini, C., et al. (2021). “Combined Metabolic Activators Therapy Ameliorates Liver Fat in Nonalcoholic Fatty Liver Disease Patients.” Mol Syst Biol 17, e10459. doi: 10.15252/msb.202110459.Zhou, B., Wang, D. D., Qiu, Y., Airhart, S., Liu, Y., Stempien-Otero, A., et al. (2020). “Boosting NAD+ Level Suppresses Inflammatory Activation of PBMC in Heart Failure.” J Clin Invest 130, 6054–6063. doi: 10.1172/jci138538.